TRCT
IPHA

Tower Research Capital (TRC)’s Innate Pharma IPHA Stock Holding History

Tower Research Capital (TRC)’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$5 – 5415
2025
Q1 		$5 Buy
+3
New +$6 ﹤0.01% 5113
2023
Q1 		– Sell
-2,954
Closed -$11K – 6055
2022
Q4 		$11K Buy
+2,954
New +$6.73K ﹤0.01% 3826
2022
Q3 		– Sell
-2,600
Closed -$7K – 6271
2022
Q2 		$7K Buy
+2,600
New +$7.57K ﹤0.01% 4799
2022
Q1 		– Sell
-410
Closed -$2K – 6310
2021
Q4 		$2K Sell
410
-6,800
-94% -$36.2K ﹤0.01% 5633
2021
Q3 		$44K Buy
+7,210
New +$31.1K ﹤0.01% 3060
2020
Q1 		– Sell
-937
Closed -$6K – 3466
2019
Q4 		$6K Buy
+937
New +$5.76K ﹤0.01% 2596

Other funds holding IPHA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $8.31B AUM 21.94% 1-Year Est. Return

Tower Research Capital (TRC)'s IPHA Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of Innate Pharma (IPHA) in Q2 2025, closing a stake of 3 shares — an estimated $5 sold.

Tower Research Capital (TRC) first reported a position in IPHA in Q4 2019 and held it in 6 quarters. The position peaked at $44K in Q3 2021. 9 funds tracked by Wall St. Rank hold IPHA as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining Innate Pharma position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3 Innate Pharma shares in Q2 2025, an estimated $5.
  • Tower Research Capital (TRC) first reported a position in Innate Pharma in Q4 2019 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Innate Pharma position peaked at $44K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.